Corporate Overview
On this page:
Baxter International Inc. (NYSE:BAX), through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. Baxter had 2012 sales of $14.2 billion and has approximately 50,800 employees.
Business Overview
BioScience
2012 Sales-$6.2 Billion
Baxter is a leading manufacturer of recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha 1-antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; products for regenerative medicine, such as biosurgery products; and vaccines.
Medical Products
2012 Sales-$8.0 Billion
Baxter’s Medical Products business manufactures products used in the delivery of fluids and drugs to patients. These include intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, IV nutrition products, infusion pumps and inhalation anesthetics. The business also provides products and services related to pharmacy compounding, drug formulation and packaging technologies. In addition, Baxter's Medical Products business is a leader in Renal home-based therapies, such as peritoneal dialysis, and offers other products and services for people with end-stage kidney disease.
2012 Sales by Business
2012 Sales by Region
Regional Employee Breakdown
|
2010
|
2011
|
2012
|
||
| United States |
19,000
|
19,000
|
20,300
|
|
| Europe |
14,500
|
15,000
|
15,500
|
|
| Latin America/Canada |
7,050
|
6,660
|
6,875
|
|
| Asia Pacific |
7,000
|
7,600
|
8,100
|
|
| Total |
47,600
|
48,500
|
50,800
|
R&D Expenditures (in millions)
Because of our longstanding commitment to research and development, Baxter’s history is rich with medical firsts, from the first commercially manufactured intravenous (IV) solutions to the first portable kidney dialysis machine, plus many more. Baxter continually pursues breakthrough technologies through research facilities around the world, and our investments reflect that commitment.
